BSX Stock Analysis: Buy, Sell, or Hold?
BSX - Boston Scientific Corp.
$93.53
1.20 (1.30%)
▲
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 04, 2026
3d
Get Alerted When BSX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: BSX shows positive signals but monitor for confirmation. Market pricing in 1.1% decline. Moderate conviction.
💡 BUY OPPORTUNITY: BSX shows positive signals but monitor for confirmation. Market pricing in 1.1% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$134.40
Based on 9.2% avg growth
INTRINSIC VALUE TODAY
$83.45
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BSX is currently trading at $93.53, which is considered fair relative to its 30-day fair value range of $91.88 to $96.93. The stock's valuation (Forward PE: 26.6) is in line with its historical norms (27.5). Remarkably, the market is currently pricing in an annual earnings decline of 1.1% over the next few years. This pessimistic expectation contrasts with the company's recent 60.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, BSX is in a downtrend. The price is approaching resistance at $94.75. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $124.41 (+34.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BSX is in a downtrend. The price is approaching resistance at $94.75. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $124.41 (+34.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$91.88 -
$96.93
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 34.7% below Wall St target ($124.41)
Fair Price Analysis
30-Day Fair Range
$91.88 -
$96.93
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$87.03
Resistance Level
$94.75
Current Trend
Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
26.59
Wall Street Target
$124.41
(+34.7%)
Revenue Growth (YoY)
20.3%
Earnings Growth (YoY)
60.0%
Profit Margin
14.4%
Valuation Discount vs History
-1.1% cheaper
PE vs Historical
26.6 vs 27.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.1%
(market-implied from PE analysis)
1-Year Target
$91.31
(-1%)
2-Year Target
$90.31
(-2%)
3-Year Target
$89.32
(-3%)
3-Yr Target (if PE normalizes)
(PE: 27→28)
$92.36
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 26.6, Growth: 14.4%)
$138.14
(+50%)
Base:
(SPY PE: 22.3, Growth: 14.4%)
$115.84
(+26%)
Bear:
(PE: 19.0, Growth: 14.4%)
$98.46
(+7%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (27x PE), but valuation improves significantly next year (27x PE) as earnings recover.
Forward PE: 26.95 | Forward EPS (Implied): $3.47
Bull Case
$112.94
(+21%)
Analyst growth 15.0%, PE expands to 28.3
Base Case
$93.53
(0%)
Market implied 0.0%, PE stable at 27.0
Bear Case
$71.55
(-24%)
Severe decline -15.0%, PE contracts to 24.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 26.6 to 27.5
Stabilization Target:
$95.48
(+3.4%)
PE Expansion Potential:
+3.4%
Last updated: January 31, 2026 1:03 PM ET
Data refreshes hourly during market hours. Next update: 2:03 PM
Data refreshes hourly during market hours. Next update: 2:03 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BSX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Joseph Michael Fitzgerald
SELL
50000 shares
2025-10-01
Val T. Hoyle
SELL
2025-09-23
Joseph Michael Fitzgerald
SELL
50000 shares
2025-09-02
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$85 | 65 BUY |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$136 | 63 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$110 | 63 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
23 analysts |
$374 | 54 HOLD |
|
ZBH
Zimmer Biomet Holdings I… |
HOLD
29 analysts |
$103 | 58 HOLD |
Advanced BSX Option Strategies
Professional options setups generated by AI based on today's BSX price and gamma walls.
